Bharat Biotech, based in India, has gained approval for human trials for their COVAXIN vaccine this Tuesday according to a press release.
We've added Bharat Biotech to our vaccine tracker, where we track the status of every COVID-19 under development on a daily basis.
The inactivated vaccine was granted permission by the Drug Controller General of India, and the Ministry of Health & Family Welfare to begin Phase I/II trials making COVAXIN the first COVID-19 vaccine in India.
“We are proud to announce COVAXIN™, India’s first indigenous vaccine against COVID-19," said Dr. Krishna Ella, Chairman and Managing Director for Bharat Biotech. "The collaboration with ICMR and NIV was instrumental in the development of this vaccine. The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform.”
The vaccine received expediency through normal Indian regulatory protocols. Bharat Biotech has also produced vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya, and Zika totaling 16 vaccines in more than 116 countries and 4 billion doses of vaccines worldwide.
“Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic." said Mrs. Suchitra Ella, Joint Managing Director of Bharat Biotech. "Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India’s strength in handling future pandemics.”